Precipio, Inc. PRPO
Nasdaq · XNAS · stock · Laboratory Analytical Instruments
Chart by TradingView
6/9
Piotroski F — financial health
-13.13
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $24.2M | -$363,000 | $10.7M | $359,000 | $14.6M |
| 2024 | $41.8M | -$4.3M | $7.6M | $216,000 | $12.1M |
| 2023 | $15.4M | — | $6.0M | -$3.7M | $14.4M |
| 2022 | $9.8M | — | $2.5M | -$8.0M | $16.4M |
| 2021 | $17.7M | — | $2.4M | -$7.3M | $24.6M |
| 2020 | $7.4M | — | $1.1M | -$7.6M | $14.2M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| SANDBERG RICHARD A | director | 2026-05-21 | Sell | 900 | $25.02 |
| SANDBERG RICHARD A | director | 2026-05-20 | Sell | 500 | $25.00 |
| SANDBERG RICHARD A | director | 2026-05-20 | Sell | 2,034 | $24.89 |
| SANDBERG RICHARD A | director | 2026-05-19 | Sell | 600 | $24.42 |
| Cohen David Seth | director | 2026-04-15 | Grant | 445 | $29.49 |
| Valauri Christina Rizopoulos | director | 2026-04-15 | Grant | 93 | $29.49 |
| Cossman Jeffrey | director | 2026-04-15 | Grant | 365 | $29.49 |
| Sabet Ahmed Zaki | Chief Operating Officer | 2026-04-01 | Buy | 19 | $27.93 |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -13.13 (distress)
- Working capital / assets 0.107
- Retained earnings / assets -4.823
- EBIT / assets -0.056
- Equity / liabilities 2.155
Source: SEC EDGAR filings · CIK 0001043961 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.